2005 FDA Approved Drugs

The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Drug information typically includes the drug name, approval status, indication of use, and clinical trial results. Review descriptions for our medical therapeutic area list to help assist in your search.

Join our Drug Research Updates group on LinkedIn! 
Find out more about the types of drugs included in this listing.

Cardiology/Vascular Diseases

BiDil (isosorbide dinitrate/hydralazine hydrochloride); NitroMed; For the treatment of heart failure in black patients, Approved June, 2005

Dermatology

Tygacil (tigecycline); Wyeth; For the treatment of complicated skin and skin structure and intra-abdominal infections and bacterial pneumonia, Approved 2005

Endocrinology

ACTOplus met (pioglitazone hydrochloride and metformin hydrochloride); Takeda; For the treatment of type 2 diabetes, Approved August of 2005

Byetta (exenatide); Amylin/Eli Lilly; For the adjunctive treatment of Type 2 diabetes mellitus, Approved April, 2005

Increlex (mecasermin); Tercica; For the treatment of growth failure due to Primary IGFD, Approved August 2005

Symlin (pramlintide); Amylin Pharmaceuticals; For the treatment of type I and type II diabetes, Approved March 2005

Family Medicine

ACTOplus met (pioglitazone hydrochloride and metformin hydrochloride); Takeda; For the treatment of type 2 diabetes, Approved August of 2005

Aptivus (tipranavir); Boehringer Ingelheim; For the adjunctive treatment of HIV-1 infections, Approved June, 2005

BiDil (isosorbide dinitrate/hydralazine hydrochloride); NitroMed; For the treatment of heart failure in black patients, Approved June, 2005

Boniva (ibandronate); Roche / GlaxoSmithKline; For the treatment and prevention of osteoporosis, Approved May, 2003 -- UPDATED: NEW FORMULATION APPROVED MARCH, 2005

Byetta (exenatide); Amylin/Eli Lilly; For the adjunctive treatment of Type 2 diabetes mellitus, Approved April, 2005

Nexavar (sorafenib); Bayer/Onyx; For the Treatment of Renal Cell Carcinoma, Approved December 2005

Orencia (abatacept); Bristol-Myers Squibb; For the Treatment of Rheumatoid Arthritis, Approved December 2005

Symlin (pramlintide); Amylin Pharmaceuticals; For the treatment of type I and type II diabetes, Approved March 2005

Tysabri (natalizumab); Elan Pharmaceuticals / Biogen Idec; For the treatment of relapsing forms of multiple sclerosis, Approved November 2004 -- Updated: Suspended February 2005--Updated: sBLA

Gastroenterology

Tygacil (tigecycline); Wyeth; For the treatment of complicated skin and skin structure and intra-abdominal infections and bacterial pneumonia, Approved 2005

Hematology

Revlimid (lenalidomide); Celgene; For the treatment of low- and intermediate-1-risk myelodysplastic syndromes, Approved December 2005

Hepatology (Liver, Pancreatic, Gall Bladder)

Baraclude (entecavir); Bristol-Myers Squibb; For the treatment of chronic hepatitis B infections with evidence of active viral replication, Approved March, 2005

Nexavar (sorafenib); Bayer/Onyx; For the Treatment of Renal Cell Carcinoma, Approved December 2005

Immunology

Aptivus (tipranavir); Boehringer Ingelheim; For the adjunctive treatment of HIV-1 infections, Approved June, 2005

Baraclude (entecavir); Bristol-Myers Squibb; For the treatment of chronic hepatitis B infections with evidence of active viral replication, Approved March, 2005

Tygacil (tigecycline); Wyeth; For the treatment of complicated skin and skin structure and intra-abdominal infections and bacterial pneumonia, Approved 2005

Infections and Infectious Diseases

Aptivus (tipranavir); Boehringer Ingelheim; For the adjunctive treatment of HIV-1 infections, Approved June, 2005

Baraclude (entecavir); Bristol-Myers Squibb; For the treatment of chronic hepatitis B infections with evidence of active viral replication, Approved March, 2005

Musculoskeletal

Boniva (ibandronate); Roche / GlaxoSmithKline; For the treatment and prevention of osteoporosis, Approved May, 2003 -- UPDATED: NEW FORMULATION APPROVED MARCH, 2005

Naglazyme (galsulfase); BioMarin Pharmaceuticals; For the treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), Approved May 2005

Nephrology

Vaprisol (conivaptan); Astellas Pharma US, Inc; For the treatment of euvolemic hyponatremia, Approved December 2005

Neurology

Rozerem (ramelteon); Takeda; For the treatment of sleep-onset insomnia, Approved July, 2005

Tysabri (natalizumab); Elan Pharmaceuticals / Biogen Idec; For the treatment of relapsing forms of multiple sclerosis, Approved November 2004 -- Updated: Suspended February 2005--Updated: sBLA

Oncology

Arranon (nelarabine); GlaxoSmithKline; For the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, Approved October 2005

Nexavar (sorafenib); Bayer/Onyx; For the Treatment of Renal Cell Carcinoma, Approved December 2005

Pulmonary/Respiratory Diseases

Tygacil (tigecycline); Wyeth; For the treatment of complicated skin and skin structure and intra-abdominal infections and bacterial pneumonia, Approved 2005

Rheumatology

Orencia (abatacept); Bristol-Myers Squibb; For the Treatment of Rheumatoid Arthritis, Approved December 2005